Abcl stock forecast.

According to 40 analysts, the average rating for MSFT stock is "Strong Buy." The 12-month stock price forecast is $392.0, which is an increase of 3.51% from the latest price.Quite a few analysts cover the stock, so you could look into forecast growth quite easily. Insider Ownership Of AbCellera Biologics The definition of company insiders can be subjective and does ...AB Capital Share Price: Find the latest news on AB Capital Stock Price. Get all the information on AB Capital with historic price charts for NSE / BSE.Analyst Recommendations on AbCellera Biologics Inc. Piper Sandler Assumes AbCellera Biologics at Overweight With $20 Price Target. Oct. 13. MT. Benchmark Adjusts AbCellera Biologics' Price Target to $12 From $20, Keeps Buy Rating. Aug. 31. MT. Goldman Sachs Adjusts AbCellera Biologics' Price Target to $24 From $27, Keeps Buy Rating.You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.

AbCellera Biologics (ABCL) Risk Factors. Public companies are required to disclose risks that can affect the business and impact the stock. These disclosures are known as “Risk Factors”. Companies disclose these risks in their yearly (Form 10-K), quarterly earnings (Form 10-Q), or “foreign private issuer” reports (Form 20-F).Dec 24, 2020 · About the AbCellera Biologics Inc stock forecast. As of 2023 November 28, Tuesday current price of ABCL stock is 4.530$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception). 1 Month Ago. -$0.12. 3 Months Ago. -$0.14. AbCellera Biologics Inc. analyst estimates, including ABCL earnings per share estimates and analyst recommendations.

JYNT. The Joint Corp. 9.24. -0.01. -0.11%. In this piece, we will take a look at 11 cheap small cap stocks to buy before the next breakout. If you want to skip out on an introduction to small cap ...

People use statistics daily for weather forecasts, predicting disease, preparing for emergencies, medical research, political campaigns, tracking sales, genetics, insurance, the stock market and quality testing.AbCellera Biologics Inc (ABCL). 4.34 -0.26 (-5.65%) USD ... Price to book value is a valuation ratio that is measured by stock price / book value per share.AbCellera Biologics Inc. company earnings calendar and analyst expectations - Upcoming and past events | Nasdaq: ABCL | NasdaqAbcellera Biologics Inc Stock Forecast, Predictions & Price Target Add to Watchlist Overview Forecast Earnings Dividend Ownership Analyst price target for ABCL All …

On September 12, 2023, Veronique Lecault, the COO of AbCellera Biologics Inc (NASDAQ:ABCL), made a significant purchase of 20,000 shares of the company's stock.

Given its relevancies, ABCL stock gained 13% of equity value in the trailing year. Still, ABCL surprisingly ranks among the most undervalued biotech stocks to buy. Currently, the market prices ...

See the latest AbCellera Biologics Inc Ordinary Shares stock price (ABCL:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Adbri (ASX:ABC) pays an annual dividend of A$0.12 per share and currently has a dividend yield of 5.74%. ABC has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 75.00%. This payout ratio is at a healthy, sustainable level, below 75%.ABCL stock's Price/Earning ratio is 12.33. Our analysis grades ABCL stock's Price / Earning ratio at F. This means that ABCL stock's Price/Earning ratio is above 62% of the stocks in the Biotechnology sector in the NSD exchange. Based on this ABCL may be a overvalued for its sector.Based on short-term price targets offered by eight analysts, the average price target for AbCellera Biologics Inc. comes to $20.75. The forecasts range from a low of $10.00 to a high of $32.00 ...Long-term ABCL price forecast for 2025, 2030, 2035, 2040, 2045 and 2050. Our analysts are offering long term price forecasts for AbCellera Biologics Inc In 2050, the median target price for ABCL is $317.20, with a high estimate of $352.81 and a low estimate of $30.87. The median estimate represents a +6,902% increase from the last price of $4. ... In today’s fast-paced business environment, accurate forecasting is crucial for making informed decisions and staying ahead of the competition. One powerful tool that can help you achieve this is a forecasting Excel template.AbCellera Biologics (ABCL) Risk Factors. Public companies are required to disclose risks that can affect the business and impact the stock. These disclosures are known as “Risk Factors”. Companies disclose these risks in their yearly (Form 10-K), quarterly earnings (Form 10-Q), or “foreign private issuer” reports (Form 20-F).

Abcellera Biologics Inc (NASDAQ:ABCL) 4.76 Delayed Data As of 3:59pm ET +0.035 / +0.74% Today’s Change 3.87 Today ||| 52-Week Range 14.00 -52.96% Year-to-Date Quote Profile News Charts...According to our current ABCL stock forecast, the value of AbCellera Biologics shares will drop by -6.13% and reach $ 4.40 per share by December 6, 2023. …According to our current BILI stock forecast, the value of Bilibili Inc. shares will drop by -8.68% and reach $ 10.31 per share by December 6, 2023. According to our technical indicators, the current sentiment is Bearish while the Fear & Greed Index is showing 39 (Fear).BILI stock recorded 13/30 (43%) green days with 6.20% price …Analyst Recommendations on AbCellera Biologics Inc. Piper Sandler Assumes AbCellera Biologics at Overweight With $20 Price Target. Oct. 13. MT. Benchmark Adjusts AbCellera Biologics' Price Target to $12 From $20, Keeps Buy Rating. Aug. 31. MT. Goldman Sachs Adjusts AbCellera Biologics' Price Target to $24 From $27, Keeps Buy Rating. The position was rebuilt in Q3 2019 at prices between ~$18.50 and ~$27. Q2 & Q4 2020 saw a two-thirds stake increase at prices between ~$12.50 and ~$57.50. There was a ~35% reduction in Q2 2021 at ...ABCL stock recorded 16/30 (53%) green days with 5.07% price volatility over the last 30 days. Based on our AbCellera Biologics stock forecast, it's now a bad time to buy ABCL stock because it's trading 6.53% above our forecast. Disclaimer: This is not investment advice. The information provided is for general information purposes only.

Abcellera Biologics Inc (ABCL) Company Description. AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various …Abcam plc () Stock Market info Recommendations: Buy or sell Abcam stock? London Stock Market & Finance report, prediction for the future: You'll find the Abcam share forecasts, stock quote and buy / sell signals below.According to present data Abcam's ABC shares and potentially its market environment have been in bearish cycle last 12 months …

What this means: InvestorsObserver gives AbCellera Biologics Inc (ABCL) an overall rank of 36, which is below average. AbCellera Biologics Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 36 means that 64% of stocks appear more favorable to our system.Earnings announcement* for ABC: May 02, 2023. AmerisourceBergen Corporation (Holding Co) is expected* to report earnings on 05/02/2023 before market open. The report will be for the fiscal Quarter ...Jul 12, 2023 · Find the latest AbCellera (NASDAQ: ABCL) stock information. 12/02/2023. Palantir stock price stood at $20.27. According to the latest long-term forecast, Palantir price will hit $25 by the end of 2023 and then $30 by the middle of 2025. Palantir will rise to $45 within the year of 2026, $55 in 2027, $60 in 2028, $65 in 2029, $70 in 2030, $75 in 2032, $80 in 2033, $85 in 2034 and $90 in 2035.A high-level overview of AbCellera Biologics Inc. (ABCL) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. The Bilibili Inc. stock forecast for tomorrow is $ 11.34, which would represent a 0.50% gain compared to the current price. In the next week, the price of BILI is expected to decrease by -8.68% and hit $ 10.31. As far as the long-term Bilibili Inc. stock forecast is concerned, here’s what our predictions are currently suggesting. Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Ownership SEC Filings Short Interest Social Media ABCL vs. SMMT, MRUS, RYZB, ARVN, IRON, AMRX, MRVI, MIRM, PCRX, and PNTADMA Stock 12 Months Forecast. $6.00. (51.90% Upside) Based on 2 Wall Street analysts offering 12 month price targets for ADMA Biologics in the last 3 months. The average price target is $6.00 with a high forecast of $7.00 and a low forecast of $5.00. The average price target represents a 51.90% change from the last price of $3.95.According to . 3 Wall Street analysts that have issued a 1 year ABCL price target, the average ABCL price target is $18.67, with the highest ABCL stock price forecast at $24.00 and the lowest ABCL stock price forecast at $12.00.

High Growth Earnings: ABCL is forecast to remain unprofitable over the next 3 years. Revenue vs Market: ABCL's revenue (23.9% per year) is forecast to grow faster than the US market (8% per year). High Growth Revenue: ABCL's revenue (23.9% per year) is forecast to grow faster than 20% per year.

AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023. Find the latest AbCellera Biologics Inc. (ABCL) stock quote, history, news and other vital …

Insiders purchased significant amount of AbCellera stock directly after Q1. See why I ABCL shares are increasingly attractive for long-term, patient investors.Earnings announcement* for ABC: May 02, 2023. AmerisourceBergen Corporation (Holding Co) is expected* to report earnings on 05/02/2023 before market open. The report will be for the fiscal Quarter ...Nov 24, 2023 · On a fall, the stock will find some support from the long-term average at approximately $4.30. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sell signal. A buy signal was issued from a pivot bottom point on Friday, October 27, 2023, and so far it has risen 13.30%. The average Palantir stock price prediction forecasts a potential downside of 27.3% from the current PLTR share price of $19.20. What is PLTR's forecast return on ...We don't have any Insights for this stock currently. Aditya Birla Cap. Share Price Returns. 1 Day, 1.67%. 1 Month ...Aditya Birla Cap. share price was Rs 169.90 as on 01 Dec, 2023, 03:59 PM IST. Aditya Birla Cap. share price was up by 1.13% based on previous share price of Rs. 169.15. In last 1 Month, Aditya Birla Cap. share price moved down by 0.12%. 2.Abcellera Biologics Inc. 4.76. Delayed Data. As of 3:59pm ET. +0.035 / +0.74%. Today’s Change. 3.87. Today ||| 52-Week Range. 14.00.Their ACN share price targets range from $279.00 to $410.00. On average, they anticipate the company's stock price to reach $337.26 in the next year. This suggests that the stock has a possible downside of 0.2%. View analysts price targets for ACN or view top-rated stocks among Wall Street analysts.

View live AbCellera Biologics Inc. chart to track its stock's price ... View live AbCellera Biologics Inc. chart to track its stock's price action. Find market predictions, ABCL financials and market ... Market closed Market closed. No trades. See on Supercharts. Overview . News Ideas Financials Technicals Forecast . ABCL chart. Today 1.06% 5 ...AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of $0.01. This compares to earnings of $0.19 per share a year ago. These ...AB Capital Share Price: Find the latest news on AB Capital Stock Price. Get all the information on AB Capital with historic price charts for NSE / BSE.Instagram:https://instagram. spirit dental reviewsvalue of mercury dimebest watercraft insurancemaserati ghibli top speed Track AbCellera Biologics Inc (ABCL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors 10.00 stocksmunicipal bonds rate of return The Bureau of Meteorology and AFAC summer outlook shows Australia is not off the hook for hot summer temperatures and a heightened bushfire risk, despite …Future criteria checks 4/6. Palantir Technologies is forecast to grow earnings and revenue by 34.8% and 18% per annum respectively. EPS is expected to grow by 33.7% per annum. Return on equity is forecast to be 18.4% in 3 years. best leadership book Nov 16, 2023 · Get powerful stock screeners & detailed portfolio analysis. Subscribe Now See Plans & Pricing. AbCellera Biologics stock news, updates & related news. Find out why AbCellera Biologics's (ABCL) news sentiment is 14.35% more negative in relation to stocks in the Healthcare sector. ABCL Stock Analysis: Impressive Performance and Optimistic Analyst Forecasts ABCL stock had an impressive performance on September 20, 2023, based on the information provided. The 7 analysts offering 12-month price forecasts for Abcellera Biologics Inc have a median target of 28.00, with a high estimate of 34.00 and a low estimate of 12.00.AbCellera Biologics ’s ( ABCL) Moving Averages Convergence Divergence (MACD) indicator is -0.21, suggesting AbCellera Biologics is a Sell. AbCellera Biologics ’s ( ABCL) 20-Day exponential moving average is 4.29, while AbCellera Biologics ’s ( ABCL) share price is $4.43, making it a Sell. AbCellera Biologics ’s ( ABCL) 50-Day ...